<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" version="2.0">

<channel>
	<title>HIV/AIDS News &amp; Information</title>
	
	<link>http://www.hiv-infected.com</link>
	<description />
	<lastBuildDate>Fri, 12 Mar 2010 14:31:39 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://feeds.feedburner.com/HivAidsNewsInformation" /><feedburner:info xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" uri="hivaidsnewsinformation" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><item>
		<title>Pharmaceutical Approval Update: Lapatinib (Tykerb)</title>
		<link>http://www.hiv-infected.com/2010/03/pharmaceutical-approval-update-lapatinib-tykerb.html</link>
		<comments>http://www.hiv-infected.com/2010/03/pharmaceutical-approval-update-lapatinib-tykerb.html#comments</comments>
		<pubDate>Fri, 12 Mar 2010 14:31:39 +0000</pubDate>
		<dc:creator>Steve</dc:creator>
				<category><![CDATA[Main]]></category>
		<category><![CDATA[Lapatinib]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Protein]]></category>

		<guid isPermaLink="false">http://www.hiv-infected.com/?p=1372</guid>
		<description><![CDATA[Manufacturer: GlaxoSmithKline, Research Triangle Park, NC
Indication: Lapatinib is indicated in combination with capecitabine (Xeloda, Roche) for patients with advanced or metastatic breast cancer whose tumors overexpress a marker called human epidermal receptor type-2 (HER-2) and who have received prior therapy, including an anthracycline, a tax-ane, and trastuzumab (Herceptin, Genentech).
Drug Class: Lapatinib is a small-molecule agent [...]]]></description>
		<wfw:commentRss>http://www.hiv-infected.com/2010/03/pharmaceutical-approval-update-lapatinib-tykerb.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmaceutical Approval Update: part 3</title>
		<link>http://www.hiv-infected.com/2010/03/pharmaceutical-approval-update-part-3.html</link>
		<comments>http://www.hiv-infected.com/2010/03/pharmaceutical-approval-update-part-3.html#comments</comments>
		<pubDate>Thu, 11 Mar 2010 14:31:39 +0000</pubDate>
		<dc:creator>Steve</dc:creator>
				<category><![CDATA[Main]]></category>
		<category><![CDATA[Lapatinib]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Protein]]></category>

		<guid isPermaLink="false">http://www.hiv-infected.com/?p=1371</guid>
		<description><![CDATA[
Metformin tablet. Hypoglycemia does not usually occur in patients receiving metformin alone, but it can occur when caloric intake is deficient, when patients do not compensate for strenuous exercise with caloric supplementation, or during concomitant use with other glucose-lowering agents (e.g., sulfonylureas and insulin) or ethanol. Elderly, debilitated, or malnourished patients and those with adrenal [...]]]></description>
		<wfw:commentRss>http://www.hiv-infected.com/2010/03/pharmaceutical-approval-update-part-3.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmaceutical Approval Update: part 2</title>
		<link>http://www.hiv-infected.com/2010/03/pharmaceutical-approval-update-part-2.html</link>
		<comments>http://www.hiv-infected.com/2010/03/pharmaceutical-approval-update-part-2.html#comments</comments>
		<pubDate>Wed, 10 Mar 2010 14:31:37 +0000</pubDate>
		<dc:creator>Steve</dc:creator>
				<category><![CDATA[Main]]></category>
		<category><![CDATA[Lapatinib]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Protein]]></category>

		<guid isPermaLink="false">http://www.hiv-infected.com/?p=1370</guid>
		<description><![CDATA[Impaired hepatic function. Impaired hepatic function has been associated with some cases of lactic acidosis. In general, sitagliptin/metformin should be avoided in patients with evidence of hepatic disease.
Assessment of renal function. Generic Metformin and sitagliptin are substantially excreted by the kidney. The risk of met formin accumulation and lactic acidosis increases with the degree of [...]]]></description>
		<wfw:commentRss>http://www.hiv-infected.com/2010/03/pharmaceutical-approval-update-part-2.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmaceutical Approval Update</title>
		<link>http://www.hiv-infected.com/2010/03/pharmaceutical-approval-update.html</link>
		<comments>http://www.hiv-infected.com/2010/03/pharmaceutical-approval-update.html#comments</comments>
		<pubDate>Tue, 09 Mar 2010 15:10:56 +0000</pubDate>
		<dc:creator>Steve</dc:creator>
				<category><![CDATA[Main]]></category>
		<category><![CDATA[Lapatinib]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Protein]]></category>

		<guid isPermaLink="false">http://www.hiv-infected.com/?p=1369</guid>
		<description><![CDATA[
Sitagliptin/Metformin drug HCl Tablets (Janumet)
Manufacturer: Merck, Inc., Whitehouse Station, NJ Indication: Sitagliptin/metformin HCl tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type-2 diabetes mellitus when glucose levels are not adequately controlled with generic metformin (Glucophage generic, Bristol-Myers Squibb) or sitagliptin (Januvia, Merck) alone or in [...]]]></description>
		<wfw:commentRss>http://www.hiv-infected.com/2010/03/pharmaceutical-approval-update.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Congress’ Remedy for Post-marketing part 3</title>
		<link>http://www.hiv-infected.com/2010/03/congress-remedy-for-post-marketing-part-3.html</link>
		<comments>http://www.hiv-infected.com/2010/03/congress-remedy-for-post-marketing-part-3.html#comments</comments>
		<pubDate>Fri, 05 Mar 2010 15:27:12 +0000</pubDate>
		<dc:creator>Steve</dc:creator>
				<category><![CDATA[Main]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[Post-marketing]]></category>

		<guid isPermaLink="false">http://www.hiv-infected.com/?p=1361</guid>
		<description><![CDATA[The agency&#8217;s own statistics for 2006 show that drug companies failed to initiate more than 70% of post-marketing studies that they committed to performing during that year; 899 of the 1,259 post-marketing studies (71%) promised had not begun as of September 30, 2006. This was an increase of 5% over fiscal year 2005. When that [...]]]></description>
		<wfw:commentRss>http://www.hiv-infected.com/2010/03/congress-remedy-for-post-marketing-part-3.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
